ArticleSignal transduction and targeted therapy2022

An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants.

Xiaojing Chi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.